Baylor University

ARTIDIS Launches Groundbreaking ANGEL Study With Over 2,700 Participants: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient's Bedside

Retrieved on: 
Thursday, November 2, 2023

The study aims to enroll over 2,700 patients, generating comprehensive insights into all breast cancer subtypes.

Key Points: 
  • The study aims to enroll over 2,700 patients, generating comprehensive insights into all breast cancer subtypes.
  • Dr. Alastair Thompson commented, “As a breast surgeon, I believe this study holds immense importance for breast cancer patients.
  • The ANGEL study specifically addresses the key challenges of personalized diagnosis and treatment decision-making, particularly in the field of neoadjuvant therapy.
  • Ensuring patients receive the best possible treatment from the start is crucial for improving outcomes for breast cancer patients.

Natural Gas Services Group, Inc. Announces the Addition of a New Director to its Board of Directors

Retrieved on: 
Monday, October 30, 2023

Ms. Hodges will join the class of directors whose term is set to expire at the 2025 annual meeting of shareholders.

Key Points: 
  • Ms. Hodges will join the class of directors whose term is set to expire at the 2025 annual meeting of shareholders.
  • “We are pleased to welcome Georganne as a director,” said Company Chairman and Interim Chief Executive Officer Stephen C. Taylor.
  • “Given her industry background, financial expertise, and public board experience we feel she will be an extremely valuable member of our Board.”
    Ms. Hodges added, "I'm thrilled to join the Board of Directors at Natural Gas Services, Inc.
  • This is an incredible team with valuable assets driving essential work in the oil and natural gas industry.

Ultima Genomics to Present at ASHG and Provide Updated Reference Data Set

Retrieved on: 
Tuesday, October 31, 2023

Watchmaker Genomics will demonstrate gene fusion detection via cost-effective whole transcriptome sequencing using the optimized Watchmaker RNA Library prep kit.

Key Points: 
  • Watchmaker Genomics will demonstrate gene fusion detection via cost-effective whole transcriptome sequencing using the optimized Watchmaker RNA Library prep kit.
  • In conjunction with the conference, Ultima will be releasing a new data set demonstrating significant improvements to the technology made through early access.
  • In particular, the data demonstrates significant improvements in indel accuracy made through a variety of advancements across chemistry and bioinformatics.
  • Industry Education Session: Empowering Genomics at Scale Thursday, Nov. 2 | Room 140AB | Talks 3:30 - 4:30 p.m.

FIVE UNSAFE SKIN CARE TRENDS TO AVOID

Retrieved on: 
Wednesday, November 1, 2023

ROSEMONT, Ill. , Nov. 1, 2023 /PRNewswire/ -- Social media platforms are rife with skin care advice from a variety of sources, which can make it difficult to know how to approach the recommendations you find online. In recognition of National Healthy Skin Month this November, board-certified dermatologists are spotlighting unsafe skin care trends that they see on social media and elsewhere to help you keep your skin looking its best.

Key Points: 
  • In recognition of National Healthy Skin Month this November, board-certified dermatologists are spotlighting unsafe skin care trends that they see on social media and elsewhere to help you keep your skin looking its best.
  • While self-tanner that you apply to your skin is a safe way to look tan, nasal tanning spray is not.
  • The sun exposure increases your risk of developing skin cancer and signs of premature skin aging like wrinkles and age spots.
  • Board-certified dermatologists have the expertise and training needed to perform cosmetic procedures and advise people on how to best care for and protect their hair, skin, and nails.

PARAPRO'S THOUGHT LEADER AI: WHERE ARTIFICIAL INTELLIGENCE MEETS SCABIES EXPERTISE

Retrieved on: 
Thursday, October 26, 2023

CARMEL, Ind., Oct. 26, 2023 /PRNewswire/ -- ParaPRO, a leading specialty pharmaceutical company specializing in innovative treatments for human ectoparasites, has unveiled Thought Leader AI. This cutting-edge decision support tool, developed in collaboration with the Institute for Creative Technologies (ICT) at the University of Southern California, enables healthcare practitioners to conduct lifelike consultations with top scabies specialists. From diagnosis to treatment, Thought Leader AI aims to support clinical decision-making and foster a virtual exchange of expert insights. Healthcare providers can visit www.thoughtleaderai.org to experience Thought Leader AI in action. Non-healthcare providers can contact [email protected] to receive instructions on how to access the platform.

Key Points: 
  • From diagnosis to treatment, Thought Leader AI aims to support clinical decision-making and foster a virtual exchange of expert insights.
  • Healthcare providers can visit www.thoughtleaderai.org to experience Thought Leader AI in action.
  • Thought Leader AI also informs clinicians about available treatment options, including the first and only FDA-approved 'complete cure' for scabies."
  • Thought Leader AI addresses these challenges head-on, allowing practitioners to seek real-time expert advice, gain invaluable clinical insights, and explore best practices.

Payne to Retire After 40 Year Career at Guaranty

Retrieved on: 
Monday, October 23, 2023

Guaranty Bancshares, Inc., (the ‘Company,’ NYSE: GNTY), the parent company of Guaranty Bank & Trust, N.A.

Key Points: 
  • Guaranty Bancshares, Inc., (the ‘Company,’ NYSE: GNTY), the parent company of Guaranty Bank & Trust, N.A.
  • ‘Cappy’ Payne, Senior Executive Vice President and Chief Financial Officer of the Company plans to retire March 31, 2024, after 40 years with the Company and 35 years as the principal accounting officer.
  • Cappy will step down as CFO effective December 29, 2023 and Shalene Jacobson will become the Company’s next CFO.
  • Shalene joined the Bank in 2016 and currently serves as Executive Vice President and Chief Financial Officer of the Bank.

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Retrieved on: 
Thursday, October 19, 2023

Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.
  • In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics.
  • “We are very pleased to welcome Andreas to Omeros’ leadership team,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.
  • He joins Omeros from Federation Bio where, as chief medical officer, he led all clinical activities with a focus on hyperoxaluria and immuno-oncology.

CARGO Therapeutics Announces Appointment of Ginna Laport, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, October 17, 2023

SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer. Dr. Laport is a seasoned biotechnology executive and senior clinical leader. She will serve on the Company’s executive team and will be responsible for providing leadership and direction to guide CARGO’s clinical development strategy and execution, including the advancement of CARGO’s lead candidate, CRG-022, as well as its pipeline of next-generation CAR T-cell therapies for cancer patients. CRG-022 is an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, currently in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Key Points: 
  • SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer.
  • “We are thrilled to announce the addition of Ginna to our team as Chief Medical Officer.
  • With her extensive leadership background in clinical drug development, particularly in hematology/oncology, she brings invaluable expertise to our organization,” said Gina Chapman, CARGO’s President and Chief Executive Officer.
  • Previously, Dr. Laport was Chief Medical Officer at Tempest Therapeutics, where she directed the clinical development of small molecules that combine both tumor-targeted and immune-mediated mechanisms, including several IND submissions.

Diakonos Oncology Awarded FDA Fast Track Designation for Innovative Dendritic Cell Vaccine for Glioblastoma

Retrieved on: 
Tuesday, October 17, 2023

Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.

Key Points: 
  • Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.
  • The designation was based on positive preliminary safety and efficacy data from a Phase 1 clinical trial enrolling patients with glioblastoma multiforme (GBM).
  • FDA Fast Track designation is intended to speed development and review of drugs that show early clinical promise in treating severe or life-threatening conditions.
  • This pivotal designation can help propel Diakonos closer to delivering DOC1021 to GBM patients, of which only 7% survive more than five years.

The AIM-HI Accelerator Fund Recognizes, Honors, and Congratulates Its 2023 Women’s Venture Competition Top Winners

Retrieved on: 
Monday, October 16, 2023

Blue-ribbon judge committee members selected them from a pool of 71 female-led, early-stage oncology companies across 15 countries.

Key Points: 
  • Blue-ribbon judge committee members selected them from a pool of 71 female-led, early-stage oncology companies across 15 countries.
  • The Phase 1 clinical trial has demonstrated strong efficacy and safety signals, with multiple long-term survivors in remission years after treatment.
  • This recognition from AIM-HI is an acknowledgment of our hard work and an affirmation of our technology platform,” said Dr. Hein.
  • In addition to the first and second-place winners, Delee was selected as The 2023 People’s Choice for “Best Pitch” by a public audience voting for their favorite pitch presentation during the 2023 Women’s Venture Competition selection process.